Syrrx Overview

  • Year Founded
  • 1999

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $270M

Syrrx General Information

Description

Developer of novel small molecule drug intended to create novel therapies for treatment of cancer, metabolic diseases and inflammation. The company performs high-throughput rational drug discovery and focuses on drug targets that have been validated in human clinical trials and directs its efforts towards therapeutics, enabling patients to get proper treatment.

Contact Information

Website
www.syrrx.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 10410 Science Center Drive
  • San Diego, CA 92121
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Takeda Pharmaceutical
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 10410 Science Center Drive
  • San Diego, CA 92121
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Syrrx Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Merger/Acquisition 08-Feb-2005 $270M Completed Generating Revenue
9. Early Stage VC 03-Dec-2003 Completed Generating Revenue
8. Early Stage VC (Series A) 25-Feb-2003 Completed Generating Revenue
7. Early Stage VC 25-Feb-2003 Completed Generating Revenue
6. Early Stage VC 10-Jan-2003 Completed Generating Revenue
5. Early Stage VC 01-Feb-2002 Completed Generating Revenue
4. Grant 15-Oct-2001 Completed Generating Revenue
3. Early Stage VC 08-Jan-2001 Completed Generating Revenue
2. Early Stage VC 03-Oct-2000 $20M $25M Completed Product Development
1. Early Stage VC 03-Aug-2000 $5M $5M Completed Product Development
To view Syrrx’s complete valuation and funding history, request access »

Syrrx Former Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds
Bay City Capital Venture Capital Minority
Bio Frontier Partners Venture Capital Minority
Canadian Imperial Bank of Commerce Investment Bank Minority
Columbia Wanger Asset Management Asset Manager Minority
Cooper Hill Partners Hedge Fund Minority
You’re viewing 5 of 16 investors. Get the full list »

Ready to get started?

Request a free trial

Syrrx FAQs

  • When was Syrrx founded?

    Syrrx was founded in 1999.

  • Where is Syrrx headquartered?

    Syrrx is headquartered in San Diego, CA.

  • What industry is Syrrx in?

    Syrrx’s primary industry is Drug Discovery.

  • Is Syrrx a private or public company?

    Syrrx is a Private company.

  • What is the current valuation of Syrrx?

    The current valuation of Syrrx is .

  • What is Syrrx’s current revenue?

    The current revenue for Syrrx is .

  • How much funding has Syrrx raised over time?

    Syrrx has raised $138M.

  • Who are Syrrx’s investors?

    Bay City Capital, Bio Frontier Partners, Canadian Imperial Bank of Commerce, Columbia Wanger Asset Management, and Cooper Hill Partners are 5 of 16 investors who have invested in Syrrx.

  • When was Syrrx acquired?

    Syrrx was acquired on 08-Feb-2005.

  • Who acquired Syrrx?

    Syrrx was acquired by Takeda Pharmaceutical.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process